CONTACTStaffCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2024 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
The Food and Drug Administration on Tuesday approved a once-daily version of Abbott Laboratories' HIV protease inhibitor Kaletra, The Wall Street Journal reports. The drug had previously been approved for twice-daily dosage. A 48-week study of 190 treatment-naive HIV-positive adults showed that once-daily dosing of the medication was as effective in controlling HIV viral replication as twice-daily dosing. Kaletra, the most frequently prescribed protease inhibitor in the United States, is recommended by the Department of Health and Human Services for use in first-line HIV therapy along with Epivir and either Retrovir or Zerit. The new once-daily formulation of Kaletra will be offered in both liquid and soft gel capsules, say Abbott officials.
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
From our Sponsors
Most Popular
Meet all 37 of the queer women in this season's WNBA
April 17 2024 11:24 AM
Here are the 15 gayest travel destinations in the world: report
March 26 2024 9:23 AM
21+ steamy photos of Scotland’s finest gay men in Elska Glasgow
February 01 2024 10:07 PM
More Than 50 of Our Favorite LGBTQ+ Moms
May 12 2024 11:44 AM
Conjoined twins Lori Schappell and trans man George Schappell dead at 62
April 27 2024 6:13 PM
Latest Stories
Two media insiders are forming a collective advocating for the community
July 19 2024 8:00 PM
Out Rep. Mark Pocan, other Dems join call for Biden to drop out
July 19 2024 7:36 PM
George Santos to gays at the RNC: 'Just come out of the closet boys'
July 19 2024 12:31 PM
Chino Valley school district sues California over new law banning forced outing
July 18 2024 6:52 PM